Bank of Montreal Can Increases Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Bank of Montreal Can lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 17.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,457 shares of the company’s stock after purchasing an additional 12,484 shares during the period. Bank of Montreal Can owned about 0.25% of TransMedics Group worth $5,141,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of TMDX. National Bank of Canada FI raised its stake in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after buying an additional 262 shares in the last quarter. MML Investors Services LLC raised its position in shares of TransMedics Group by 140.3% during the 3rd quarter. MML Investors Services LLC now owns 4,123 shares of the company’s stock worth $647,000 after acquiring an additional 2,407 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of TransMedics Group during the 3rd quarter worth about $368,000. Geode Capital Management LLC lifted its stake in TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after purchasing an additional 10,106 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in TransMedics Group in the third quarter valued at approximately $436,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on TMDX shares. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $86.84 on Tuesday. The stock has a fifty day moving average price of $71.19 and a 200 day moving average price of $80.67. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market cap of $2.92 billion, a PE ratio of 92.38 and a beta of 2.14.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.